NASDAQ:XNCRXencor Stock Price, Forecast & News

Xencor's stock was trading at $28.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, XNCR stock has increased by 14.7% and is now trading at $32.25. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 3 sell ratings, 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Xencor.

Xencor is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Xencor.

Xencor Inc (NASDAQ:XNCR) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.42) by $0.28. The biopharmaceutical company earned $32.39 million during the quarter, compared to the consensus estimate of $12.33 million. Xencor had a negative net margin of 79.39% and a negative return on equity of 10.40%. View Xencor's earnings history.

11 analysts have issued 1-year price objectives for Xencor's shares. Their forecasts range from $21.00 to $67.00. On average, they expect Xencor's stock price to reach $42.60 in the next year. This suggests a possible upside of 32.1% from the stock's current price. View analysts' price targets for Xencor.

Media headlines about XNCR stock have trended very negative on Thursday, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Xencor earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Xencor.

Some companies that are related to Xencor include Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Myokardia (MYOK), Emergent Biosolutions (EBS), Blueprint Medicines (BPMC), Biohaven Pharmaceutical (BHVN) and Nektar Therapeutics (NKTR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Cypress Semiconductor (CY), Apollo Global Management (APO), Intel (INTC), AbbVie (ABBV), Exelixis (EXEL), Fossil Group (FOSL), NVIDIA (NVDA) and Abercrombie & Fitch (ANF).

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XNCR stock can currently be purchased for approximately $32.25.

Xencor has a market capitalization of $1.84 billion and generates $156.70 million in revenue each year. The biopharmaceutical company earns $26.88 million in net income (profit) each year or $0.46 on an earnings per share basis. Xencor employs 156 workers across the globe.

The official website for Xencor is www.xencor.com.

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]